Reprogrammed tumor cells could boost immunotherapy
An international study led from Lund University shows that cancer cells reprogrammed into immune cells can help organize the immune system’s attack inside tumors. The findings, from experiments in mice, could pave the way for immunotherapies that work for more patients.
Immunotherapy has transformed cancer care, but many patients still don’t respond, particularly those with hard-to-treat cancers. Some tumors contain small clusters of immune cells, called tertiary lymphoid structures (TLS), that help coordinate the immune response. Patients whose tumors have these clusters respond better to immunotherapy and often live longer. Getting TLS to form, however, takes the right combination of inflammatory signals, immune cells, and tumor environment.
“Until now, it has been difficult to get TLS to form, because there have been no good methods for studying and engineering these structures in different types of tumors in the lab. We have now developed a new strategy to address this challenge,” says Filipe Pereira, professor of molecular medicine at Lund University, who led the study.
In earlier work, Pereira’s group showed that cancer cells inside a tumor can be reprogrammed into dendritic cells, a type of immune cell that helps the body mount a response against the tumor. The new study shows that these reprogrammed cells can also drive the formation of TLS and organize the immune attack.
In mice, the method activated the immune system against several cancer types, including melanoma and colon, bladder, breast, and pancreatic cancer.
“The results suggest that the method has the potential to fight several types of cancer, including those that are usually resistant to immunotherapy. It could pave the way for new immunotherapies,” says Pereira.
Next, the researchers want to find out which signals make TLS form and persist over time, and how the method can be combined with existing immunotherapies.
Published: November 16, 2026
